Bactana
Latest round
- Series A
Last raised
- Mar 2017
Total raised
- Undisclosed
Investors
- 2
About Bactana
Bactana Corp. focuses on health innovations by developing unique solutions for gut and metabolic health.Bactana specializes in the development and production of innovative health solutions primarily targeting intestinal and metabolic health through its unique offerings of probiotics and postbiotics. The company’s core product line includes patented formulations derived from small molecules isolated from proprietary anaerobic cell lines, designed to facilitate the health of both animals and humans. Their flagship product, Pawsni™ Metabolic Health, serves as a therapeutic supplement aimed at pets, addressing metabolic conditions and digestive disorders. Bactana's products are distributed in various geographical markets, including North America and Canada, where they cater to veterinarians, pet owners, and livestock producers seeking alternatives to traditional antibiotics.Bactana generates revenue through direct sales of its innovative health solutions, particularly its core product offerings like Pawsni™ Metabolic Health. The company engages in B2B transactions with veterinary clinics, pet retailers, and livestock producers, establishing partnerships that facilitate the distribution of their products. Transactions typically involve wholesale agreements where retailers purchase products in bulk to resell to end consumers, encapsulating a structured pricing model that reflects the premium nature of the formulations. While specific pricing details for individual products are not disclosed, the company’s approach emphasizes building long-term relationships with its client base, which includes veterinarians and health-conscious pet owners.On May 13, 2025, Kemin Industries Inc. agreed to acquire Bactana Corp. The acquisition aims to enable Kemin Industries to venture into emerging technologies that improve gut health in pets and other animals. This strategic move will likely support Bactana’s plans for expanding its product offerings and distribution channels in new geographic markets.
Who invested in Bactana
2 investors across 1 round
See all investors in Bactana
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Mar 28, 2017
Amount
Undisclosed
Investors
Questions about Bactana
Who invested in Bactana?
Bactana has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Bactana raised?
Bactana has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Bactana last raise money?
Bactana's most recent round on record is a Series A, in Mar 2017.
What does Bactana do?
Bactana is a biotechnology company.
Where is Bactana headquartered?
Bactana is headquartered in Farmington, US.
Which VCs invest in companies like Bactana?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Bactana's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Bactana? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.